{"id":39322,"date":"2026-08-07T11:18:00","date_gmt":"2026-08-07T15:18:00","guid":{"rendered":"https:\/\/www.drugpatentwatch.com\/blog\/exelixis-inc-v-intas-pharmaceuticals-ltd\/"},"modified":"2026-07-08T00:14:12","modified_gmt":"2026-07-08T04:14:12","slug":"exelixis-inc-v-intas-pharmaceuticals-ltd","status":"publish","type":"post","link":"https:\/\/www.drugpatentwatch.com\/blog\/exelixis-inc-v-intas-pharmaceuticals-ltd\/","title":{"rendered":"Exelixis, Inc. v. Intas Pharmaceuticals Ltd."},"content":{"rendered":"<h2><strong>Exelixis v. Intas (1:26-cv-00814): Litigation Summary, Patent Claims, and Potential Generic Entry Impact<\/strong><\/h2>\n<h3><strong>Executive summary<\/strong><\/h3>\n<ul>\n<li><strong>Case<\/strong>: Exelixis, Inc. v. Intas Pharmaceuticals Ltd.  <\/li>\n<li><strong>Court\/docket<\/strong>: U.S. District Court, 1:26-cv-00814  <\/li>\n<li><strong>Core issue<\/strong>: Patent infringement and related relief tied to an Exelixis product and\/or its Orange Book-listed patents, asserted against Intas in the context of generic or alternative entry under <strong>Hatch-Waxman<\/strong>.<\/li>\n<li><strong>Business impact to watch<\/strong>: Whether the asserted patents include <strong>composition, formulation, method-of-use, or manufacturing<\/strong> claims, and whether Intas\u2019s application is likely positioned for a <strong>Paragraph IV<\/strong> attack or a <strong>carve-out\/section 505(b)(2)<\/strong> pathway. The scope and claim selection drive both <strong>design-around feasibility<\/strong> and the <strong>timing risk<\/strong> for generic launch.<\/li>\n<\/ul>\n<p>No litigation filings, claim charts, complaint text, or patent list were provided in the prompt. Without the underlying docket contents (complaint, answers, motions, and PTAB\/Fed. Cir. activity if any), a complete and accurate litigation summary cannot be produced.<\/p>\n<h3><strong>What patents are at issue in Exelixis v. Intas 1:26-cv-00814?<\/strong><\/h3>\n<p><strong>Answer (required for an infringement and exclusivity-risk\u2026<\/strong><\/p>","protected":false},"excerpt":{"rendered":"<p>Exelixis v. Intas (1:26-cv-00814): Litigation Summary, Patent Claims, and Potential Generic Entry Impact Executive summary Case: Exelixis, Inc. v. Intas [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":34556,"comment_status":"open","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[10],"tags":[],"class_list":["post-39322","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-insights"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/39322","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/comments?post=39322"}],"version-history":[{"count":1,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/39322\/revisions"}],"predecessor-version":[{"id":39403,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/39322\/revisions\/39403"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media\/34556"}],"wp:attachment":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media?parent=39322"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/categories?post=39322"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/tags?post=39322"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}